Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 12/2019

Open Access 01-12-2019 | Molecular Imaging | Invited Review Article

From the respective expert viewpoints of the ANM specialty editors

Authors: Masayuki Inubushi, Miho Shidahara, Yasuyuki Takahashi, Mikako Ogawa, Yasushi Kiyono

Published in: Annals of Nuclear Medicine | Issue 12/2019

Login to get access

Abstract

Although it may not be well known, the Annals of Nuclear Medicine (ANM) Editorial Committee includes one specialty editor of nuclear medicine physics, one of nuclear medicine technology, one of molecular imaging, and two of radiopharmacology. In addition, a statistics editor and a language editor are also on the committee. Manuscripts submitted to ANM can be peer-reviewed by such specialty editors similar to those submitted to highly ranked journals, which is a great pride and joy to us. To offer our readers a condensed global view on the high-quality research work in the field of nuclear medicine, we have published a mini-review article every year under the joint authorship of the ANM associate editors since 2016. This is our fourth serial review article written by the ANM specialty editors from their respective expert viewpoints.
Literature
1.
Inubushi M, Higashi T, Kuji I, Sakamoto S, Tashiro M, Momose M. Introduction of nuclear medicine research in Japan. Eur J Nucl Med Mol Imaging. 2016;43:2449–522.CrossRef
2.
Inubushi M, Kaneta T, Ishimori T, Imabayashi E, Okizaki A, Oku N. Topics of nuclear medicine research in Europe. Ann Nucl Med. 2017;31:571–4.CrossRef
3.
Inubushi M, Tatsumi M, Yamamoto Y, Kato K, Tsujikawa T, Nishii R. European research trends in nuclear medicine. Ann Nucl Med. 2018;32:579–82.CrossRef
4.
Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, et al. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging. 2018;45:2426–41.CrossRef
5.
Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33–41.CrossRef
6.
Kratochwil C, Schmidt K, Afshar-Oromieh A, Bruchertseifer F, Rathke H, Morgenstern A, et al. Targeted alpha therapy of mCRPC: dosimetry estimate of 213Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018;45:31–7.CrossRef
7.
Kaalep A, Sera T, Rijnsdorp S, Yaqub M, Talsma A, Lodge MA, et al. Feasibility of state of the art PET/CT systems performance harmonisation. Eur J Nucl Med Mol Imaging. 2018;45:1344–61.CrossRef
8.
Klein Jan GH, van Werkhoven E, van den Berg NS, Karakullukcu MB, Zijlmans HJMAA, van der Hage JA, van de Wiel BA, Buckle T, Klop WMC, Horenblas S, Olmos VRA, van der Poel HG, van Leeuwen FWB. The best of both worlds: a hybrid approach for optimal pre- and intraoperative identification of sentinel lymph nodes. Eur J Nucl Med Mol Imaging. 2018;45:1915–25.CrossRef
9.
Yang X, Liu Z, Zhang H, Li Z, Munasinghe JP, Niu G, Teng G, Chen X. Preclinical evaluation of an 18F-trifluoroborate methionine derivative for glioma imaging. Eur J Nucl Med Mol Imaging. 2018;45:585–92.CrossRef
10.
Ohshima Y, Sudo H, Watanabe S, Nagatsu K, Tsuji AB, Sakashita T, et al. Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model. Eur J Nucl Med Mol Imaging. 2018;45:999–1010.CrossRef
11.
Ehlerding EB, Lacognata S, Jiang D, Ferreira CA, Goel S, Hernandez R, et al. Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody. Eur J Nucl Med Mol Imaging. 2018;45:123–31.CrossRef
12.
Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, et al. PSMA targeted radioligand therapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2018;45:12–9.CrossRef
13.
Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, et al. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:243–6.CrossRef
14.
Rahbar K, Ahmadzadehfar H, Boegemann M. 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial? Eur J Nucl Med Mol Imaging. 2018;45:513–4.CrossRef
15.
von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2018;45:496–508.CrossRef
16.
Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:471–95.CrossRef
17.
Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, Schlyer D, et al. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. Eur J Nucl Med Mol Imaging. 2018;45:1841–51.CrossRef
Metadata
Title
From the respective expert viewpoints of the ANM specialty editors
Authors
Masayuki Inubushi
Miho Shidahara
Yasuyuki Takahashi
Mikako Ogawa
Yasushi Kiyono
Publication date
01-12-2019
Publisher
Springer Singapore
Published in
Annals of Nuclear Medicine / Issue 12/2019
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-019-01421-1

Other articles of this Issue 12/2019

Annals of Nuclear Medicine 12/2019 Go to the issue

Original Article

Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer

Editorial

An appreciation from the out-going editor-in-chief

Original Article

PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels

Original Article

Association between carotid 18F-NaF and 18F-FDG uptake on PET/CT with ischemic vascular brain disease on MRI in patients with carotid artery disease

Original Article

Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma

Short Communication

Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients